PDCD1 and systemic lupus erythematosus: Given the patient’s stable SLE, she received tislelizumab - the only PD-1 monoclonal antibody with government-sponsored medical insurance coverage for MSI-H solid tumor indications in China, (200 mg intravenously once every 3 weeks) on January 19, 2024, and was successfully discharged post-treatment.